Amgen Inc (AMGN)

AMGN (NASDAQ:Drugs) EQUITY
$156.34
neg -3.30
-2.00%
Today's Range: 156.89 - 159.92 | AMGN Avg Daily Volume: 3,615,700
Last Update: 03/06/15 - 11:34 AM EST
Volume: 964,883
YTD Performance: 0.19%
Open: $158.50
Previous Close: $159.60
52 Week Range: $108.20 - $173.14
Oustanding Shares: 758,861,306
Market Cap: 120,803,131,302
6-Month Chart
TheStreet Ratings Grade for AMGN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 6 5 5 5
Moderate Buy 2 2 2 2
Hold 8 8 7 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.09 2.17 2.11 2.11
Latest Dividend: 0.79
Latest Dividend Yield: 1.98%
Dividend Ex-Date: 02/10/15
Price Earnings Ratio: 23.76
Price Earnings Comparisons:
AMGN Sector Avg. S&P 500
23.76 23.80 27.74
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-5.70% 26.48% 137.39%
GROWTH 12 Mo 3 Yr CAGR
Revenue 7.40 0.29 0.09
Net Income 1.50 0.40 0.12
EPS 0.90 0.67 0.18
Earnings for AMGN:
EBITDA 8.74B
Revenue 20.06B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $2.09 $2.38 $9.36 $10.53
Number of Analysts 10 9 13 11
High Estimate $2.40 $2.45 $9.75 $11.23
Low Estimate $1.95 $2.29 $9.21 $10.08
Prior Year $1.86 $2.37 $8.68 $9.36
Growth Rate (Year over Year) 12.20% 0.61% 7.81% 12.52%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Update
Mar 02, 2015 | 7:50 AM EST
Cowen Health Care Conference (Day 1 of 3) - 03/02/15 - 03/04/15 Boston, M
The debate raging among investors about hepatitis C revenue declines.

Braving Biotech Real Money Pro($)

Do you need to pick one name?
They are prone to being whipsawed by news.
Update
Jan 06, 2015 | 7:48 AM EST
AMGN was initiated with an Equal-weight rating, Barclays said. Company will struggle to sustain the momentum from 2014. $180 price targ...
Bearish
Jan 05, 2015 | 6:34 AM EST
AMGN was downgraded to Equal-weight from Overweight, Morgan Stanley said. $177 price target. Valuation call, as the company lacks near-...

Right and Wrong Real Money Pro($)

Every trade should have a thesis and a catalyst.

2 Names Top My Watch List Real Money Pro($)

Why I'm looking at the iShares Biotech ETF and Amgen.
A litany of reasons why you should calm your nerves.
In this era of turmoil, investors can take comfort in this sector.

Columnist Conversations

if you wanted to counter Goldman's downgrade you could use the same line of reasoning that JJC has been using ...
Two days ago, I noted that Weyerhaeuser (WY) had broken channel support, and yesterday commented on the contin...
Where was Goldman Sachs when Lulu ran from the low 40s to the mid 60s? I believe they were neutral at the time...
I will take a shot at LULU slightly lower than current levels. The stock's 2014 high is $59.85, just belo...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.